Street Calls of the Week
PONTE VEDRA, Fla. - Treace Medical Concepts, Inc. (NASDAQ:TMCI), a medical technology company currently valued at $352 million, announced Tuesday the publication of four-year interim results from its ALIGN3D multicenter study showing positive outcomes for its Lapiplasty Procedure for bunion correction. According to InvestingPro data, the company maintains impressive gross margins of 80%, though its stock has declined 47% over the past six months.
The peer-reviewed data, published in the Journal of Foot & Ankle Surgery, included 139 patients with at least four years of follow-up. Results demonstrated a low radiographic recurrence rate of 0.8% using the hallux valgus angle greater than 20 degrees as the threshold, and 8.4% using the more stringent threshold of greater than 15 degrees.
Patients in the study returned to protected weight bearing at an average of 7.7 days and to athletic shoes at 6.5 weeks post-procedure. The data also showed an 81% improvement in pain and 89% improvement in walking/standing on the Manchester Oxford Foot Questionnaire scoring system through the 48-month follow-up period.
"By consistently performing a comprehensive 3D correction of the bunion deformity, the recurrence rates with the Lapiplasty Procedure are very low and compare favorably to long-term studies of traditional osteotomy with high rates of recurrence," said Daniel Hatch, DPM, of the Foot and Ankle Center of the Rockies and a publication author.
The ALIGN3D clinical study enrolled 173 patients aged 14 to 58 years at seven clinical sites in the United States with 13 participating surgeons. Final five-year data from the study is expected in 2026.
Treace Medical Concepts develops medical technology focused on the surgical treatment of bunions and related midfoot deformities. The company estimates that of the approximately 65 million Americans with bunions, about 1.1 million are annual surgical candidates. Despite the large market opportunity, InvestingPro analysis suggests the company is currently undervalued, with additional ProTips and detailed financial metrics available to subscribers, including comprehensive analysis of the company’s growth potential and market position.
The information was disclosed in a company press release.
In other recent news, Treace Medical Concepts Inc reported its Q1 2025 earnings, revealing a revenue of $52.6 million. This figure slightly missed the forecast of $52.7 million. The company reported an earnings per share (EPS) of -$0.25, which was in line with expectations set by analysts. Despite the slight revenue miss, the earnings announcement was met with positive investor sentiment. Analysts from various firms had anticipated the EPS outcome, which likely contributed to the stable reaction. Treace Medical Concepts did not announce any mergers or acquisitions during this period. Additionally, there were no recent analyst upgrades or downgrades reported for the company. These developments reflect the company’s current financial standing and market perception.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.